Personalized medicine uses information about a person, their genes, and their disease to choose prevention, diagnosis, and treatment strategies. Pharmacogenomics is a major part of this approach because gene variants can change how a patient absorbs, breaks down, or responds to a drug. This matters because the same dose can help one patient, fail in another, or cause serious side effects in a third.
By combining clinical data with genetic testing, doctors can make treatment choices that are more precise and safer.
Understanding Personalized Medicine
A medicine has to travel through the body before it can do its job. It may be absorbed from the gut, carried in the blood, changed by the liver, and removed by the kidneys. Small inherited differences can affect each step.
Some people make an enzyme that works slowly. The drug can then remain in the body longer and build up. Other people make a very active enzyme.
Their body may clear the drug before it has enough time to work. Blood concentration is important because too little treatment may fail, while too much can cause harm. Doctors consider age, body mass, liver function, kidney function, other medicines, and genetic test results when these factors are relevant.
Drug interactions show why a genetic result is only one part of the picture. A person may have genes linked with normal drug breakdown, yet another medicine can block the same liver enzyme. Certain foods, smoking, illness, and alcohol use can alter drug handling too.
This means a result from a DNA test does not predict the exact outcome with certainty. It gives useful evidence about likely risk. Clinicians still watch for symptoms, measure blood levels for some medicines, and adjust treatment over time.
Students should separate a predicted response from an observed response. The predicted response comes from biological clues. The observed response comes from what happens in the real patient.
Cancer treatment uses a related idea, but the DNA test often examines the tumor rather than inherited DNA. Cancer cells gain mutations as they grow. Some mutations produce proteins that send constant signals telling cells to divide.
A targeted drug may block one of these abnormal signals. Before treatment, a laboratory can test a biopsy or sometimes a blood sample for a biomarker. The result helps show whether a particular drug is likely to have a target to act on.
Tumors are not always uniform. One area of a tumor may differ from another, and cancer cells can change during treatment.
A therapy can work at first, then resistant cells may survive and multiply. Repeat testing can help explain this change.
Personalized medicine does not mean that every patient receives a completely unique drug. It means treatment decisions use the best available evidence for that person and that illness. Some test results are strongly linked to a clear prescribing decision.
Others are less certain because studies are limited or results vary across groups. Test quality matters. A sample can be too small, contaminated, or unable to detect every relevant change.
Privacy matters too, since genetic information can reveal facts about biological relatives. When learning this topic, focus on the chain of cause and effect. A DNA variant may change a protein.
The protein may change drug movement or a cell signal. That change can affect benefit, side effects, or the dose a clinician chooses.
Key Facts
- Pharmacogenomics studies how genes affect drug response.
- CYP450 enzymes help metabolize many drugs, and CYP2D6, CYP2C9, and CYP2C19 are common examples.
- Drug exposure is often estimated by AUC = total drug in blood over time.
- Warfarin dose can be influenced by variants in CYP2C9 and VKORC1.
- Targeted cancer therapy can match a drug to a tumor mutation, such as HER2-positive breast cancer treated with HER2-targeted drugs.
- Genotype is inherited DNA information, while phenotype is the observable trait or drug response.
Vocabulary
- Personalized medicine
- Personalized medicine is medical care tailored to a patient's genes, environment, lifestyle, and disease features.
- Pharmacogenomics
- Pharmacogenomics is the study of how genetic differences affect a person's response to medicines.
- CYP450 enzymes
- CYP450 enzymes are liver proteins that chemically modify many drugs so they can be activated, inactivated, or removed from the body.
- Biomarker
- A biomarker is a measurable biological sign, such as a gene variant or protein level, that helps guide diagnosis or treatment.
- Tumor sequencing
- Tumor sequencing is the analysis of cancer cell DNA to find mutations that may guide targeted therapy.
Common Mistakes to Avoid
- Assuming one genetic test predicts response to every drug is wrong because different drugs are affected by different genes and pathways.
- Treating all CYP450 variants as harmful is wrong because some variants reduce metabolism, some increase metabolism, and some have little clinical effect.
- Using tumor sequencing results as if they are always inherited is wrong because many cancer mutations are somatic and exist only in tumor cells.
- Ignoring non-genetic factors is wrong because age, kidney function, liver function, diet, drug interactions, and adherence can also strongly affect treatment response.
Practice Questions
- 1 A standard dose of a drug is 100 mg. A patient has a genotype that reduces metabolism, so the clinician starts at 50 percent of the standard dose. What starting dose should be used?
- 2 In a clinic of 240 patients taking clopidogrel, 15 percent have a CYP2C19 variant that may reduce activation of the drug. How many patients have this variant?
- 3 A breast cancer tumor tests positive for HER2 overexpression, but the patient's normal cells do not carry a HER2 mutation. Explain why this result can still guide treatment without meaning the mutation was inherited.